https://www.eurekalert.org/pub_releases/2021-06/dci-idd060321.php
News Release 3-Jun-2021
Dana-Farber Cancer Institute
Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.
•••••
No comments:
Post a Comment